Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of single-dose GBI268 injection for postoperative analgesia after unilateral hallux valgus osteotomy
CTR20261823Phase 3Active
- Sponsor
- Guangzhou Zhiyao Biotechnology
- Start
- Jun 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of GBI268 in acute postoperative pain, sponsored by Guangzhou Zhiyao Biotechnology. Started Jun 2026; status: active.
02
Drugs
GBI268
03
Conditions
acute postoperative pain
Beyond the preview
Go deeper on CTR20261823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261823.